Industry attention is focused on the fate of the two new drugs that were unable to pass the final stage to reimbursement in Korea.

According to industry sources, Ono Pharma Korea’s colorectal cancer drug Braftovi (encorafenib) and Novartis' retinal disease drug Luxterna (voretigene neparvovec-rzyl) have entered into extended negotiations with the National Health Insurance Service after failing to reach an agreement on their drug prices by the deadline.

As a result, the two drugs will remain non-reimbursed until next year, unable not to be reimbursed in January 2024.

The extended negotiations are likely due to delays in the companies’ headquarters approval of the final dr